The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021.
Apart from reducing hospitalisation for the most vulnerable group and its efficacy against Omicron variants, Paxlovid has also shown to decrease the chances of long COVID-19.
A daily round-up of the most interesting articles to help jump-start the day.
The pill treatment Paxlovid brought in $7.5 billion in sales in the quarter and has generated more than $17 billion so far this year.
Paxzen, a two-drug combination, is the generic version of Pfizer's anti-covid pill Paxlovid. A box of Paxzen will cost Rs 5,200
The physician, Dr. Kevin O’Connor, wrote in a letter released Friday that Biden was still experiencing a runny nose and fatigue and that he had an “occasional nonproductive, now ‘loose’ cough.”
US President Joe Biden tested positive for COVID-19 on July 21. He is experiencing mild symptoms and will continue working, the White House said.
Late-stage clinical trials showed Paxlovid cut hospitalisation and death risks in mild to moderately high-risk COVID-19 patients by up to 88 percent and new evidence is emerging that it is also dramatically effective in treating long COVID symptoms
Studies showed the drug called Paxlovid reduces hospitalisation and death in patients at risk of severe Covid, and may also be effective against the Omicron variant.
Are these medications effective against Omicron? This week Pfizer published a media release detailing preliminary results suggesting Paxlovid is still effective against the Omicron variant.
In a statement issued Tuesday, Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53 percent of the world’s population.